Journal articles: 'Pharmaceutical aerosols'

1

Gonda, Igor. "Pharmaceutical Aerosols." Journal of Aerosol Medicine 5, no. 2 (January 1992): 123–25. http://dx.doi.org/10.1089/jam.1992.5.123a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Saliy, О. О., M. E. Popova, H. V. Tarasenko, and V. S. Yarovenko. "Analysis and systematization of the main market trends development in pressurized pharmaceutical preparations in pharmaceutical and veterinary practice." Social Pharmacy in Health Care 8, no. 3 (October 12, 2022): 60–70. http://dx.doi.org/10.24959/sphhcj.22.263.

Full text

Abstract:

Aim. Analysis and systematization of the main market trends development in pressurized pharmaceutical preparations in pharmaceutical and veterinary practice. Materials and methods. Methods of systematic approach, bibliographic methods, information retrieval, analysis, comparison and generalization, statistical processing, tabular and graphic means of visual presentation of the obtained data were used during the market research. The analysis of registered in Ukraine pressurized pharmaceutical preparations was carried out based on the data of the State Register of Medicinal Products of Ukraine, “Morion” information search program, the Anatomical Therapeutic Chemical (ATC) Classification of electronic resource Compendium.online and the list of registered veterinary medicinal products. Research results. The paper presents the results of the marketing analysis of the Ukraine pharmaceutical market of pressurized pharmaceutical preparations for medical and veterinary practice. As of April 2022, the total number of registered medicinal products is 65 names, of which 58 (89,23%) are for medical purposes and 7 (10,77%) for veterinary purposes. The studied drugs in the form of aerosols are represented by 8 anatomical groups for use in medicine and 3 anatomical groups for veterinary practice. The market segmentation of these drug groups was carried out in accordance with the classification of ATC, by active substance, producing countries, type of propellant and field of purpose. It was determined that the share of aerosols for inhalation (Antiasthmatics) is 53.85%, aerosols for use in the oral cavity - 15.38%, aerosols for local use - 12.3%. Conclusions. The analysis of the Ukraine pharmaceutical market in pressurised pharmaceutical preparations segment shows an increase in domestic market of pharmaceuticals not only in number of products, but also in medical indications of pharmaceuticals and veterinary drugs. The modern production facilities and the modern technologies of development for the production of metered aerosols remains an important factor in the market growth. A promising direction is the creation of foam drugs in the form of aerosols for the prevention and treatment of gynecological diseases, intrauterine infections and dermatological lesions.

APA, Harvard, Vancouver, ISO, and other styles

3

Mishra, Raghav, and Radhika Agarwal. "A Concise Overview on Recent Advances in Pharmaceutical Aerosols and their Commercial Applications." Current Materials Science 15, no. 2 (July 2022): 125–41. http://dx.doi.org/10.2174/2666145414666211111102425.

Full text

Abstract:

Background: Localized drug delivery to the respiratory system has become an increasingly successful and essential treatment strategy for several pulmonary diseases, including asthma, chronic abstractive disease, pneumonia, bronchitis, and cystic fibrosis. The rising incidence of respiratory diseases is a significant factor driving the worldwide market for respiratory inhaler devices. Objective: The objective of this article is to present various aspects of pharmaceutical aerosols, including their types, components, fundamentals, in-process and finished product quality control tests based on pharmacopeial standards and specifications, and commercial utility considering the pharmaceutical aerosol dosage forms that have been patented from 2000 to 2020, along with a list of marketed pharmaceutical products. Method: Aerosol, collectively referred to as a pressurized device, operates by triggering an appropriate valve system with a continuous or metered dosage of tiny mist spray. It is used not only in the treatment of asthma and chronic obstructive pulmonary disease but also in the treatment of cancer, diabetes, migraine, angina pectoris, acute lung injury, bone disorders, tuberculosis, and many more. A multitude of different variables, including types and properties of propellants, active substances, containers, valves, actuators, spray patterns, valve crimping efficiency, and particle size of the aerosols, influence the therapeutic effectiveness of pharmaceutical aerosols. Conclusion: Based on the current findings, distinct characteristics such as the elimination of firstpass metabolism, quick drug absorption, ease of therapy termination, as well as a larger surface area have attributed to the success of pharmaceutical aerosols.

APA, Harvard, Vancouver, ISO, and other styles

4

Martí-Bonmatí, Ezequiel, Gustavo Juan, Luis Martí-Bonmatí, and Mercedes Ramon. "Effect of Low Temperatures on Drug-Delivery Efficacy of Aerosols." Journal of Pharmacy Technology 12, no. 5 (September 1996): 220–22. http://dx.doi.org/10.1177/875512259601200508.

Full text

Abstract:

Objective: To determine how low temperatures affect the pharmaceutical properties of oral inhalation aerosols pressurized with chlorofluorocarbons (CFCs). Design: Inhalation aerosols of the beta-adrenergic receptor agonist terbutaline sulfate were exposed at three different environmental temperatures [22, 0, and −10 °C; (±2)]. Three groups of 10 canisters each, at different drug loads (100%, 50%, and 20%), were studied at these temperatures. Canisters with mouthpieces were weighed before and after 40 actuations in order to study the mass propelled in each experimental condition. Photographs were also taken of the aerosol mist at each temperature. Results: A statistically significant decrease in the average mass of the aerosol discharged was evidenced at low temperatures. The temperature and aerosol output were linearly correlated. The weight loss at–10 °C was 35.4%. At this temperature the emitted doses were discharged as liquefied droplets. This effect was quickly manifested and proved reversible. Conclusions: Low temperatures modify the pharmaceutical properties of oral inhalation aerosols pressurized with CFCs. This technical information should be included as a note of caution in the prescribing information.

APA, Harvard, Vancouver, ISO, and other styles

5

Colbeck, I., and J. Amass. "Electrostatic interparticle forces -pharmaceutical aerosols." Journal of Aerosol Science 28 (September 1997): S283—S284. http://dx.doi.org/10.1016/s0021-8502(97)85142-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Colbeck, I., and J. Amass. "Dispersive interparticle forces -pharmaceutical aerosols." Journal of Aerosol Science 29 (September 1998): S765—S766. http://dx.doi.org/10.1016/s0021-8502(98)90565-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Colbeck, I., and J. Amass. "Polarisation interparticle forces -pharmaceutical aerosols." Journal of Aerosol Science 29 (September 1998): S767—S768. http://dx.doi.org/10.1016/s0021-8502(98)90566-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kwok, Philip Chi Lip, and Hak-Kim Chan. "Electrostatics of pharmaceutical inhalation aerosols." Journal of Pharmacy and Pharmacology 61, no. 12 (December 2009): 1587–99. http://dx.doi.org/10.1211/jpp.61.12.0002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kwok, Philip Chi Lip, and Hak-Kim Chan. "Electrostatics of pharmaceutical inhalation aerosols." Journal of Pharmacy and Pharmacology 61, no. 12 (December 1, 2009): 1587–99. http://dx.doi.org/10.1211/jpp/61.12.0002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Swift, David L. "Dose Distribution of Pharmaceutical Aerosols." Aerosol Science and Technology 18, no. 3 (January 1993): 272–78. http://dx.doi.org/10.1080/02786829308959604.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Pasteka, Richard, Lara Alina Schöllbauer, Joao Pedro Santos da Costa, Radim Kolar, and Mathias Forjan. "Experimental Evaluation of Dry Powder Inhalers during Inhalation and Exhalation Using a Model of the Human Respiratory System (xPULM™)." Pharmaceutics 14, no. 3 (February 24, 2022): 500. http://dx.doi.org/10.3390/pharmaceutics14030500.

Full text

Abstract:

Dry powder inhalers are used by a large number of patients worldwide to treat respiratory diseases. The objective of this work is to experimentally investigate changes in aerosol particle diameter and particle number concentration of pharmaceutical aerosols generated by four dry powder inhalers under realistic inhalation and exhalation conditions. To simulate patients undergoing inhalation therapy, the active respiratory system model (xPULM™) was used. A mechanical upper airway model was developed, manufactured, and introduced as a part of the xPULM™ to represent the human upper respiratory tract with high fidelity. Integration of optical aerosol spectrometry technique into the setup allowed for evaluation of pharmaceutical aerosols. The results show that there is a significant difference (p < 0.05) in mean particle diameter between inhaled and exhaled particles with the majority of the particles depositing in the lung, while particles with the size of (>0.5 μm) are least influenced by deposition mechanisms. The fraction of exhaled particles ranges from 2.13% (HandiHaler®) over 2.94% (BreezHaler®), and 6.22% (Turbohaler®) to 10.24% (Ellipta®). These values are comparable to previously published studies. Furthermore, the mechanical upper airway model increases the resistance of the overall system and acts as a filter for larger particles (>3 μm). In conclusion, the xPULM™ active respiratory system model is a viable option for studying interactions of pharmaceutical aerosols and the respiratory tract regarding applicable deposition mechanisms. The model strives to support the reduction of animal experimentation in aerosol research and provides an alternative to experiments with human subjects.

APA, Harvard, Vancouver, ISO, and other styles

12

Angel, A., J. Robson, T. L. Muchnick, R. C. Moretz, and R. B. Patel. "SEM evaluation of pharmaceutical inhalation aerosols deposited in an andersen cascade impactor." Proceedings, annual meeting, Electron Microscopy Society of America 50, no. 2 (August 1992): 1328–29. http://dx.doi.org/10.1017/s0424820100131279.

Full text

Abstract:

Particle size characterization is a critical parameter used for inhalation aerosol formulation development, batch control and product performance evaluation. Both the United States Pharmacopeia optical microscopy method and multistage cascade impaction methods are used for particle size evaluation and control of inhalation aerosols. Particle size determination based on aerodynamic properties is considered more relevant than other techniques for assessing product performance during patient-use. The cascade impaction technique for evaluation of inhalation aerosols is typically used with a suitable inlet to facilitate introduction of the aerosol spray into the impactor. The drug particles deposited on the impaction stages are extracted and analyzed by an appropriate method to relate drug mass to the aerodynamic cut-off size and thereby determine respirable fractions (particles of < 5.8 μm aerodynamic size). This approach does not provide information relating to the physical character of the formulation (aggregates, agglomerates, particle shapes and morphology) or its deposition characteristics both within and between stages.

APA, Harvard, Vancouver, ISO, and other styles

13

Wong, Jennifer, Hak-Kim Chan, and Philip Chi Lip Kwok. "Electrostatics in pharmaceutical aerosols for inhalation." Therapeutic Delivery 4, no. 8 (August 2013): 981–1002. http://dx.doi.org/10.4155/tde.13.70.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Wolff, R. K., and M. A. Dorato. "Toxicologic Testing of Inhaled Pharmaceutical Aerosols." Critical Reviews in Toxicology 23, no. 4 (January 1993): 343–69. http://dx.doi.org/10.3109/10408449309104076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Voss, Austin, and Warren H. Finlay. "Deagglomeration of dry powder pharmaceutical aerosols." International Journal of Pharmaceutics 248, no. 1-2 (November 2002): 39–50. http://dx.doi.org/10.1016/s0378-5173(02)00319-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Schreier, Hans. "Liposome Aerosols." Journal of Liposome Research 2, no. 2 (January 1992): 145–84. http://dx.doi.org/10.3109/08982109209018634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Golshahi, Laleh, P. Worth Longest, Landon Holbrook, Jessica Snead, and Michael Hindle. "Production of Highly Charged Pharmaceutical Aerosols Using a New Aerosol Induction Charger." Pharmaceutical Research 32, no. 9 (March 31, 2015): 3007–17. http://dx.doi.org/10.1007/s11095-015-1682-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

McGrath, James A., Andrew O’Sullivan, Gavin Bennett, Ciarraí O’Toole, Mary Joyce, Miriam A. Byrne, and Ronan MacLoughlin. "Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation." Pharmaceutics 11, no. 2 (February 12, 2019): 75. http://dx.doi.org/10.3390/pharmaceutics11020075.

Full text

Abstract:

Background: Secondary inhalation of medical aerosols is a significant occupational hazard in both clinical and homecare settings. Exposure to fugitive emissions generated during aerosol therapy increases the risk of the unnecessary inhalation of medication, as well as toxic side effects. Methods: This study examines fugitively-emitted aerosol emissions when nebulising albuterol sulphate, as a tracer aerosol, using two commercially available nebulisers in combination with an open or valved facemask or using a mouthpiece with and without a filter on the exhalation port. Each combination was connected to a breathing simulator during simulated adult breathing. The inhaled dose and residual mass were quantified using UV spectrophotometry. Time-varying fugitively-emitted aerosol concentrations and size distributions during nebulisation were recorded using aerodynamic particle sizers at two distances relative to the simulated patient. Different aerosol concentrations and size distributions were observed depending on the interface. Results: Within each nebuliser, the facemask combination had the highest time-averaged fugitively-emitted aerosol concentration, and values up to 0.072 ± 0.001 mg m−3 were recorded. The placement of a filter on the exhalation port of the mouthpiece yielded the lowest recorded concentrations. The mass median aerodynamic diameter of the fugitively-emitted aerosol was recorded as 0.890 ± 0.044 µm, lower the initially generated medical aerosol in the range of 2–5 µm. Conclusions: The results highlight the potential secondary inhalation of exhaled aerosols from commercially available nebuliser facemask/mouthpiece combinations. The results will aid in developing approaches to inform policy and best practices for risk mitigation from fugitive emissions.

APA, Harvard, Vancouver, ISO, and other styles

19

Murthy, G. Lakshmana, Majunath U. Machale, Vasia, N. Balireddy, and C. Chandrika. "Out Lines of Aerosols in Pharmaceutical Technology." Asian Journal of Research in Pharmaceutical Science 9, no. 3 (2019): 215. http://dx.doi.org/10.5958/2231-5659.2019.00034.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lip Kwok, Philip. "Electrostatics of Pharmaceutical Aerosols for Pulmonary Delivery." Current Pharmaceutical Design 21, no. 27 (September 17, 2015): 3945–54. http://dx.doi.org/10.2174/1381612821666150820110407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

CLARK, A. R., S. P. NEWMAN, and N. DASOVICH. "Mouth and Oropharyngeal Deposition of Pharmaceutical Aerosols." Journal of Aerosol Medicine 11, s1 (June 1998): S—116—S—121. http://dx.doi.org/10.1089/jam.1998.11.suppl_1.s-116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Seemann, S., G. A. Ferron, R. Nieβner, K. Willeke, and J. Heyder. "Production of coated and monodisperse pharmaceutical aerosols." Journal of Aerosol Science 26 (September 1995): S621—S622. http://dx.doi.org/10.1016/0021-8502(95)97218-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sievers, R. E., E. T. S. Huang, J. A. Villa, J. K. Kawamoto, M. M. Evans, and P. R. Brauer. "Low-temperature manufacturing of fine pharmaceutical powders with supercritical fluid aerosolization in a Bubble Dryer®." Pure and Applied Chemistry 73, no. 8 (August 1, 2001): 1299–303. http://dx.doi.org/10.1351/pac200173081299.

Full text

Abstract:

Aerosols play an important role in thin film deposition, fine powder generation, and drug delivery. Green processes to form aerosols are needed to eliminate the use of toxic organic solvents and minimize the production of liquid wastes and the emission of halogenated and oxidant-forming organic compounds. We have developed a new patented process, Carbon Dioxide-Assisted Nebulization with a Bubble Dryer® (CAN-BD), that can generate a dense aerosol with small droplet and microbubble sizes that are dried to form particles less than 3 µm in diameter [19]. The process uses carbon dioxide as an aerosolization aid, and this permits drying at lower temperature than usually needed in conventional spray-drying. Intimate mixing of supercritical carbon dioxide with aqueous protein solutions causes the formation of microbubbles, which are rapidly dried in less than 5 s. The process is more environmentally benign than traditionally used methods, and is superior when thermally unstable materials are being processed. Fine-particle pharmaceutical powders can be rapidly and easily made by this new CAN-BD process, requiring less energy and eliminating residues of toxicologically or environmentally objectionable solvents. Manufacturing dry powders of pharmaceuticals for pulmonary drug delivery and increasing bioavailability are the purposes of developing and marketing the new Temco Bubble Dryer.

APA, Harvard, Vancouver, ISO, and other styles

24

Borojeni, Azadeh A. T., Wanjun Gu, Bahman Asgharian, Owen Price, Andrew P. Kuprat, Rajesh K. Singh, Sean Colby, Richard A. Corley, and Chantal Darquenne. "In Silico Quantification of Intersubject Variability on Aerosol Deposition in the Oral Airway." Pharmaceutics 15, no. 1 (January 3, 2023): 160. http://dx.doi.org/10.3390/pharmaceutics15010160.

Full text

Abstract:

The extrathoracic oral airway is not only a major mechanical barrier for pharmaceutical aerosols to reach the lung but also a major source of variability in lung deposition. Using computational fluid dynamics, deposition of 1–30 µm particles was predicted in 11 CT-based models of the oral airways of adults. Simulations were performed for mouth breathing during both inspiration and expiration at two steady-state flow rates representative of resting/nebulizer use (18 L/min) and of dry powder inhaler (DPI) use (45 L/min). Consistent with previous in vitro studies, there was a large intersubject variability in oral deposition. For an optimal size distribution of 1–5 µm for pharmaceutical aerosols, our data suggest that >75% of the inhaled aerosol is delivered to the intrathoracic lungs in most subjects when using a nebulizer but only in about half the subjects when using a DPI. There was no significant difference in oral deposition efficiency between inspiration and expiration, unlike subregional deposition, which shows significantly different patterns between the two breathing phases. These results highlight the need for incorporating a morphological variation of the upper airway in predictive models of aerosol deposition for accurate predictions of particle dosimetry in the intrathoracic region of the lung.

APA, Harvard, Vancouver, ISO, and other styles

25

Berlinski, Ariel, and Joshua Spiva. "In Vitro Characterization of Aerosolized Albuterol Generated by a Jet Nebulizer and Delivered through a Heated Flow Nasal Cannula System." Pharmaceuticals 15, no. 10 (October 18, 2022): 1281. http://dx.doi.org/10.3390/ph15101281.

Full text

Abstract:

Pediatric patients receiving respiratory support with heated flow nasal cannula (HFNC) systems frequently receive inhaled medications. Most available data have been obtained with vibrating mesh nebulizers that are expensive. Data are lacking regarding the feasibility of using less expensive devices such as continuous output jet nebulizers. The characteristics of the aerosols generated by jet nebulizers operated at different conditions (6 and 9 L/min) were studied alone and connected to a HFNC system and different size cannulas using a cascade impactor and spectrophotometry (276 nm). Aerosol characteristics changed while traveling through the HFNC system. Initial size selection occurred at the exit of the circuit (before connecting to the cannula) with all aerosol <5 µm. Nasal cannula size further selected aerosols and reduced drug delivery. The operating flow of the nebulizer did not affect the delivered mass but higher flows generated smaller particle size aerosols. The addition of supplemental flow significantly reduced the delivered mass. The measured aerosol characteristics would likely result in intrapulmonary deposition. The delivery of aerosolized albuterol generated by a continuous output nebulizer placed in the inlet of a HFNC system and connected to large or XXL cannulas is feasible.

APA, Harvard, Vancouver, ISO, and other styles

26

Hickey, Anthony J., and Philip Chi Lip Kwok. "In vitro-in vivo correlation of pharmaceutical aerosols." Advanced Drug Delivery Reviews 179 (December 2021): 114025. http://dx.doi.org/10.1016/j.addr.2021.114025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Dunber, Craig A., Anthony J. Hickey, and Peter Holzner. "Dispersion and Characterization of Pharmaceutical Dry Powder Aerosols." KONA Powder and Particle Journal 16 (1998): 7–45. http://dx.doi.org/10.14356/kona.1998007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Garcia-Contreras, Lucila, and Anthony J. Hickey. "Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy." Advanced Drug Delivery Reviews 54, no. 11 (December 2002): 1491–504. http://dx.doi.org/10.1016/s0169-409x(02)00159-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Byron, Peter R. "Physicochemical Effects on Lung Disposition of Pharmaceutical Aerosols." Aerosol Science and Technology 18, no. 3 (January 1993): 223–29. http://dx.doi.org/10.1080/02786829308959599.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Li, Xihao, Frank E. Blondino, Michael Hindle, William H. Soine, and Peter R. Byron. "Stability and characterization of perphenazine aerosols generated using the capillary aerosol generator." International Journal of Pharmaceutics 303, no. 1-2 (October 2005): 113–24. http://dx.doi.org/10.1016/j.ijpharm.2005.07.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Shen, X., M. Hindle, and P. R. Byron. "Effect of energy on propylene glycol aerosols using the capillary aerosol generator." International Journal of Pharmaceutics 275, no. 1-2 (May 2004): 249–58. http://dx.doi.org/10.1016/j.ijpharm.2004.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Crowder, T., and A. Hickey. "Powder specific active dispersion for generation of pharmaceutical aerosols." International Journal of Pharmaceutics 327, no. 1-2 (December 2006): 65–72. http://dx.doi.org/10.1016/j.ijpharm.2006.07.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Seemann, S., B. Busch, G. A. Ferron, A. Silberg, and J. Heyder. "Measurement of the hygroscopicity of pharmaceutical aerosols in situ." Journal of Aerosol Science 26 (September 1995): S537—S538. http://dx.doi.org/10.1016/0021-8502(95)97176-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kim, Yong-Hyun, Mi-Kyung Song, and Kyuhong Lee. "A Study on the Behavior Patterns of Liquid Aerosols Using Disinfectant Chloromethylisothiazolinone/Methylisothiazolinone Solution." Molecules 26, no. 19 (September 22, 2021): 5725. http://dx.doi.org/10.3390/molecules26195725.

Full text

Abstract:

This study evaluates the behavioral characteristics of components (methylisothiazolinone (MIT) and chloromethylisothiazolinone (CMIT)) contained in disinfectant solutions when they convert to liquid aerosols. The analytical method for MIT and CMIT quantitation was established and optimized using sorbent tube/thermal desorber-gas chromatography-mass spectrometry system; their behavioral characteristics are discussed using the quantitative results of these aerosols under different liquid aerosol generation conditions. MIT and CMIT showed different behavioral characteristics depending on the aerosol mass concentration and sampling time (sampling volume). When the disinfectant solution was initially aerosolized, MIT and CMIT were primarily collected on glass filter (MIT = 91.8 ± 10.6% and CMIT = 90.6 ± 5.18%), although when the generation and filter sampling volumes of the aerosols increased to 30 L, the relative proportions collected on the filter decreased (MIT = 79.0 ± 12.0% and CMIT = 39.7 ± 8.35%). Although MIT and CMIT had relatively high vapor pressure, in liquid aerosolized state, they primarily accumulated on the filter and exhibited particulate behavior. Their relative proportions in the aerosol were different from those in disinfectant solution. In the aerosol with mass concentration of ≤5 mg m−3, the relative proportion deviations of MIT and CMIT were large; when the mass concentration of the aerosol increased, their relative proportions constantly converged at a lower level than those in the disinfectant solution. Hence, it can be concluded that the behavioral characteristics and relative proportions need to be considered to perform the quantitative analysis of the liquid aerosols and evaluate various toxic effects using the quantitative data.

APA, Harvard, Vancouver, ISO, and other styles

35

Kenjereš, Saša, and Jimmy Leroy Tjin. "Numerical simulations of targeted delivery of magnetic drug aerosols in the human upper and central respiratory system: a validation study." Royal Society Open Science 4, no. 12 (December 2017): 170873. http://dx.doi.org/10.1098/rsos.170873.

Full text

Abstract:

In the present study, we investigate the concept of the targeted delivery of pharmaceutical drug aerosols in an anatomically realistic geometry of the human upper and central respiratory system. The geometry considered extends from the mouth inlet to the eighth generation of the bronchial bifurcations and is identical to the phantom model used in the experimental studies of Banko et al. (2015 Exp. Fluids 56 , 1–12 ( doi:10.1007/s00348-015-1966-y )). In our computer simulations, we combine the transitional Reynolds-averaged Navier–Stokes (RANS) and the wall-resolved large eddy simulation (LES) methods for the air phase with the Lagrangian approach for the particulate (aerosol) phase. We validated simulations against recently obtained magnetic resonance velocimetry measurements of Banko et al. (2015 Exp. Fluids 56 , 1–12. ( doi:10.1007/s00348-015-1966-y )) that provide a full three-dimensional mean velocity field for steady inspiratory conditions. Both approaches produced good agreement with experiments, and the transitional RANS approach is selected for the multiphase simulations of aerosols transport, because of significantly lower computational costs. The local and total deposition efficiency are calculated for different classes of pharmaceutical particles (in the 0.1 μm≤ d p ≤10 μm range) without and with a paramagnetic core (the shell–core particles). For the latter, an external magnetic field is imposed. The source of the imposed magnetic field was placed in the proximity of the first bronchial bifurcation. We demonstrated that both total and local depositions of aerosols at targeted locations can be significantly increased by an applied magnetization force. This finding confirms the possible potential for further advancement of the magnetic drug targeting technique for more efficient treatments for respiratory diseases.

APA, Harvard, Vancouver, ISO, and other styles

36

Yang, Michael Yifei, John Gar Yan Chan, and Hak-Kim Chan. "Pulmonary drug delivery by powder aerosols." Journal of Controlled Release 193 (November 2014): 228–40. http://dx.doi.org/10.1016/j.jconrel.2014.04.055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

CLARK, A. R., I. GONDA, and M. T. NEWHOUSE. "Introduction Towards Meaningful Laboratory Tests for Evaluation of Pharmaceutical Aerosols." Journal of Aerosol Medicine 11, s1 (June 1998): S—1—S—7. http://dx.doi.org/10.1089/jam.1998.11.suppl_1.s-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Skubacz, Krystian, Robert Hildebrandt, Aleksandra Zgórska, Zdzisław Dyduch, Krzysztof Samolej, and Adam Smolinski. "Transport of Aerosols in Underground Mine Workings in Terms of SARS-CoV-2 Virus Threat." Molecules 26, no. 12 (June 8, 2021): 3501. http://dx.doi.org/10.3390/molecules26123501.

Full text

Abstract:

This paper presents a method of implementation and the results of aerosol dispersion tests in underground mine workings. Numerous tests were carried out to determine the potential risk of SARS-CoV-2 coronavirus infection in the underground environment of the mines. The influence of selected parameters of mine air on the possibility and method of aerosol transmission through ventilation routes was experimentally determined in real conditions. The concentration of additional aerosols in the class of ultrafine and fine aerosols increased with the distance from the generator, while the concentration of coarse particles decreased. Assuming the consumption of the solution with which aerosols were generated, even at a small level of 1 cm3/min., the number of additional aerosols was several hundred particles in one cubic centimeter of air at a distance of 50–70 m from the generator. The concentration of ultrafine particles in the range of 40–20,000 nm increased from 122 particles/cm3 to 209 particles/cm3 at air temperature of 12 °C and relative humidity of 95–96%, and from 90 particles/cm3 to 243 particles/cm3 at air temperature of 17 °C and relative humidity of 76–82%, with the increasing distance from the generator (10 m to 50 m).

APA, Harvard, Vancouver, ISO, and other styles

39

Shachar-Berman, Lihi, Saurabh Bhardwaj, Yan Ostrovski, Prashant Das, Pantelis Koullapis, Stavros Kassinos, and Josué Sznitman. "In Silico Optimization of Fiber-Shaped Aerosols in Inhalation Therapy for Augmented Targeting and Deposition across the Respiratory Tract." Pharmaceutics 12, no. 3 (March 5, 2020): 230. http://dx.doi.org/10.3390/pharmaceutics12030230.

Full text

Abstract:

Motivated by a desire to uncover new opportunities for designing the size and shape of fiber-shaped aerosols towards improved pulmonary drug delivery deposition outcomes, we explore the transport and deposition characteristics of fibers under physiologically inspired inhalation conditions in silico, mimicking a dry powder inhaler (DPI) maneuver in adult lung models. Here, using computational fluid dynamics (CFD) simulations, we resolve the transient translational and rotational motion of inhaled micron-sized ellipsoid particles under the influence of aerodynamic (i.e., drag, lift) and gravitational forces in a respiratory tract model spanning the first seven bifurcating generations (i.e., from the mouth to upper airways), coupled to a more distal airway model representing nine generations of the mid-bronchial tree. Aerosol deposition efficiencies are quantified as a function of the equivalent diameter (dp) and geometrical aspect ratio (AR), and these are compared to outcomes with traditional spherical particles of equivalent mass. Our results help elucidate how deposition patterns are intimately coupled to dp and AR, whereby high AR fibers in the narrow range of dp = 6–7 µm yield the highest deposition efficiency for targeting the upper- and mid-bronchi, whereas fibers in the range of dp= 4–6 µm are anticipated to cross through the conducting regions and reach the deeper lung regions. Our efforts underscore previously uncovered opportunities to design the shape and size of fiber-like aerosols towards targeted pulmonary drug delivery with increased deposition efficiencies, in particular by leveraging their large payloads for deep lung deposition.

APA, Harvard, Vancouver, ISO, and other styles

40

Muralidharan, Priya, Don Hayes, Jeffrey R. Fineman, Stephen M. Black, and Heidi M. Mansour. "Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery." Pharmaceutics 13, no. 12 (December 17, 2021): 2188. http://dx.doi.org/10.3390/pharmaceutics13122188.

Full text

Abstract:

Pulmonary hypertension (PH) is a progressive disease that eventually leads to heart failure and potentially death for some patients. There are many unique advantages to treating pulmonary diseases directly and non-invasively by inhalation aerosols and dry powder inhalers (DPIs) possess additional unique advantages. There continues to be significant unmet medical needs in the effective treatment of PH that target the underlying mechanisms. To date, there is no FDA-approved DPI indicated for the treatment of PH. Fasudil is a novel RhoA/Rho kinase (ROCK) inhibitor that has shown great potential in effectively treating pulmonary hypertension. This systematic study is the first to report on the design and development of DPI formulations comprised of respirable nanoparticles/microparticles using particle engineering design by advanced spray drying. In addition, comprehensive physicochemical characterization, in vitro aerosol aerosol dispersion performance with different types of human DPI devices, in vitro cell-drug dose response cell viability of different human respiratory cells from distinct lung regions, and in vitro transepithelial electrical resistance (TEER) as air-interface culture (AIC) demonstrated that these innovative DPI fasudil formulations are safe on human lung cells and have high aerosol dispersion performance properties.

APA, Harvard, Vancouver, ISO, and other styles

41

Wu, Lang, Shuchang Lei, Yixia Wang, Shiyu Yang, Xiaoyan Lin, and Haijun Wang. "A Highly Efficient Biomass Compound Aerosol Suppressant in Purifying Radioactive Cesium Droplet Aerosols." Molecules 27, no. 19 (October 1, 2022): 6480. http://dx.doi.org/10.3390/molecules27196480.

Full text

Abstract:

Nuclear accidents and decommissioning in the nuclear industry would release a large number of radioactive aerosols which endangers the natural environment and the health of workers. Therefore, there is an urgent need for environment-friendly aerosol suppressants to control and handle environmental pollution problems caused by radioactive aerosols. In this paper, sodium alginate (SA), a type of polyphenol material (TP), and alkyl glycosides (APGs) were selected as the components of the compound aerosol suppressant and the optimal proportion was generated via the method of D-optimal mixture design. Furthermore, the cesium aerosol sedimentation effect of the optimized compound aerosol suppressants was evaluated via sedimentation efficiency, the change in particle concentration cumulative concentration fraction of the cesium aerosol sedimentation process. The results showed that the aerosol sedimentation efficiency was 99.82% which was much higher than nature settlement, 18.6% and water spraying sedimentation, 43.3%. Moreover, after spraying the compound suppressant, it displayed a good effect on settling the cesium aerosol particles with a diameter of less than 1 µm, as the concentration of particles was reduced from 55.49% to 44.53%. Finally, the sedimentation mechanism of the compound aerosol suppressant and cesium aerosol particles, such as the coagulation effect, was analyzed using the particle size distribution.

APA, Harvard, Vancouver, ISO, and other styles

42

Byron, Peter R., Michael Hindle, Carlos F. Lange, P. Worth Longest, Donald McRobbie, Michael J. Oldham, Bo Olsson, Charles G. Thiel, Herbert Wachtel, and Warren H. Finlay. "In Vivo–In VitroCorrelations: Predicting Pulmonary Drug Deposition from Pharmaceutical Aerosols." Journal of Aerosol Medicine and Pulmonary Drug Delivery 23, S2 (December 2010): S—59—S—69. http://dx.doi.org/10.1089/jamp.2010.0846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Borgström, Lars, Andy Clark, and Bo Olsson. "Introduction 1000 Years of Pharmaceutical Aerosols: What Remains to Be Done?" Journal of Aerosol Medicine and Pulmonary Drug Delivery 23, S2 (December 2010): S—1—S—4. http://dx.doi.org/10.1089/jamp.2010.0848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Longest, Worth, Benjamin Spence, and Michael Hindle. "Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs." Journal of Aerosol Medicine and Pulmonary Drug Delivery 32, no. 5 (October 1, 2019): 317–39. http://dx.doi.org/10.1089/jamp.2018.1508.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Khanal, Dipesh, Jing Zhang, Wei-Ren Ke, Mark M. Banaszak Holl, and Hak-Kim Chan. "Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols." Analytical Chemistry 92, no. 12 (May 14, 2020): 8323–32. http://dx.doi.org/10.1021/acs.analchem.0c00729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Gallimore, Peter J., Nick M. Davidson, Markus Kalberer, Francis D. Pope, and Andrew D. Ward. "1064 nm Dispersive Raman Microspectroscopy and Optical Trapping of Pharmaceutical Aerosols." Analytical Chemistry 90, no. 15 (June 29, 2018): 8838–44. http://dx.doi.org/10.1021/acs.analchem.8b00817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Chan, Hak-Kim. "What is the role of particle morphology in pharmaceutical powder aerosols?" Expert Opinion on Drug Delivery 5, no. 8 (August 2008): 909–14. http://dx.doi.org/10.1517/17425247.5.8.909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Waldrep, J. C., J. Arppe, K. A. Jansa, and V. Knight. "High dose cyclosporin A and budesonide-liposome aerosols." International Journal of Pharmaceutics 152, no. 1 (June 1997): 27–36. http://dx.doi.org/10.1016/s0378-5173(97)04912-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Gonda, Igor, Ahmed Farid Abd El Khalik, and Adam Z. Britten. "Hexamethylmelamine aerosols prepared in an evaporation-condensation generator." International Journal of Pharmaceutics 27, no. 2-3 (December 1985): 255–65. http://dx.doi.org/10.1016/0378-5173(85)90074-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sahakijpijarn, Sawittree, Hugh D. C. Smyth, Danforth P. Miller, and Jeffry G. Weers. "Post-inhalation cough with therapeutic aerosols: Formulation considerations." Advanced Drug Delivery Reviews 165-166 (2020): 127–41. http://dx.doi.org/10.1016/j.addr.2020.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Pharmaceutical aerosols'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles